Immunic (IMUX) Insider Jon Congleton Buys 50,740 Shares
Jon Congleton bought 50,740 shares of Immunic, Inc. on June 29, 2026, valued at approximately $780,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jon Congleton bought 50,740 shares of Immunic, Inc. ($IMUX) on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IMUX is down 3.6% after 1 week, down 15.3% after 1 month and down 54.8% to date (from the $15.41 close on Jun 29, 2026).
IMUX
Immunic, Inc.
Key Points
- Jon Congleton purchased 50,740 shares of IMUX on June 29, 2026, valued at about $780,000 based on a price of $15.41 per share.
- Other insiders also bought shares on the same day, with Simona Skerjanec, Richard Alan Rudick, Barclay Phillips, Tamar Howson, and Joerg Neermann each acquiring 25,370 shares.
- Analysts maintain a strong outlook for Immunic, Inc., with a mean price target of $43.09 and a consensus recommendation of 'strong buy.'
Get $IMUX trade alerts by text
We text you when insiders, Congress or big funds trade $IMUX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immunic, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Immunic, Inc.
Jon Congleton bought 50,740 shares of Immunic, Inc. (NasdaqCM: IMUX) on June 29, 2026. This purchase is valued at approximately $780,000, given the share price of $15.41 at the time of the transaction.
A Wave of Insider Buying
Congleton's purchase comes alongside several other insiders who also bought shares on the same day. Simona Skerjanec, Richard Alan Rudick, Barclay Phillips, Tamar Howson, and Joerg Neermann each acquired 25,370 shares. This collective buying suggests confidence in the company's prospects.
Analysts Set New Price Targets
Analysts have a positive outlook on Immunic, Inc. Wedbush recently reiterated its 'Outperform' rating with a price target of $45.00 on September 10, 2026. HC Wainwright & Co. also reiterated a 'Buy' rating with a target of $22.00 on the same date. The average price target among analysts is $43.09, reflecting strong expectations for the company's future performance.
About Immunic, Inc.
Immunic, Inc. is a biotechnology company based in New York, focusing on developing oral immunology therapies for chronic inflammatory and autoimmune diseases. Its lead program, IMU-838, is currently in advanced clinical trials for multiple sclerosis and ulcerative colitis.
What’s Next for Immunic?
Investors will be watching for the next earnings report scheduled for November 12, 2026. The recent insider purchases and analyst ratings could signal a positive trend for the company, though the 13F filings reflect past positions and may not represent current holdings.
Related Filing Alerts
Source: Jon Congleton's Form 4 filing on $IMUX (Jun 29, 2026). Find the original filing: IMUX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts